$2.27 0.12 (+5.58%)
11/6/2009 4:00 PM

Neurocrine Biosciences, Inc. (NBIX)

CAPS Rating: 3 out of 5

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.

Current Price $2.27 Mkt Cap $89M
Open $2.12 P/E Ratio 0.00
Prev. Close $2.15 Div. (Yield) N/A (N/A)
Daily Range $2.12 - $2.29 Volume 258,399
52-Wk Range $2.00 - $4.41 Avg. Daily Vol. 129,000

NBIX News and Commentary

Caps

This ticker is not currently Ratable.

Add Stock to Watchlist

All Members

302 Outperform
28 Underperform
 

All-Star Members

90 Outperform
11 Underperform
 

Wall Street

2 Outperform
2 Underperform
 

Top NBIX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.36)
Submitted April 01, 2009

The recent mixed results for the 702 study have created a green thumb opportunity in CAPS, although I would hesitate to buy shares in a sketchy outfit like Neurocrine with real money. In this study, also known as Lilac PETAL (barf), several different… More

cashsage (60.05)
Submitted October 18, 2009

NBIX has a too high valuation compared to its sales potential. It is also loss making at least until 2011. Its stock price may be more than halved.

NBIX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about NBIX.

Recs

1
Member Avatar cashsage (60.05) Submitted: 10/18/2009 3:57:22 PM : Underperform Start Price: $2.89 NBIX Score: +19.67

NBIX has a too high valuation compared to its sales potential. It is also loss making at least until 2011. Its stock price may be more than halved.

Recs

0
Member Avatar padparadsha (81.60) Submitted: 8/19/2009 10:44:37 AM : Outperform Start Price: $2.99 NBIX Score: -32.75

Promising recent results for Elagolix. I believe the corticotropin antagonists will become the new standard for treating IBS, depression, anxiety and even schizophrenia.
I will be buying this for my real portfolio

Recs

3
Member Avatar zzlangerhans (99.36) Submitted: 3/31/2009 11:04:47 PM : Outperform Start Price: $3.27 NBIX Score: -61.19

The recent mixed results for the 702 study have created a green thumb opportunity in CAPS, although I would hesitate to buy shares in a sketchy outfit like Neurocrine with real money. In this study, also known as Lilac PETAL (barf), several different outcome measurements were used which virtually guaranteed mixed results. Of course in Neurocrine's PR they dismissed all the non-significant outcomes as irrelevant and wholeheartedly embraced the significant results. If anyone believes they wouldn't have done the exact opposite had the outcomes been reversed, I have a cure for melanoma that I'd like to sell you. On the other hand, Intermune stock actually went up after much more foreboding mixed results in a late stage trial.

Why did Neurocrine take it on the chin? Possibly because of their history of misleading investors on the cruddy sleep drug Indiplon. Not much trust left. But I think a larger reason was the heading of an article that came out from thestreet.com shortly after trading began that day - Neurocrine's Elagolix Misses Main Study Goal. The article itself, by Adam Feuerstein, was far more even-handed than the heading. But Feuerstein has become much more influential than companies and insitutions are willing to admit. If anyone doubts, take a look back and see how he hastened Introgen into their well-deserved coffin.

I respect AF a lot, and consider him one of the best sources for opinionated biotech market research. And as he has pointed out, his editors write the headings. But it's very interesting to see how a choice of words can have such a strong short-term effect on share price. My prediction is that Neurocrine will continue on track as though the trial was a success, pending data from the four arm leuprolide comparator trial in Q3. The share price will return to an equilibrium and I will again move to the sidelines before the next binary catalyst. I'm planning to hold on to my Neurocrine score leader position.

Leaderboard

Find the members with the highest scoring picks in NBIX.

Score Leader

TiVoShane

TiVoShane (85.06) Score: +100.93

Score leader in NBIX on CAPS, big money loser in my brokerage account.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
TMFKrusty 67.39 5/17/2006 Underperform 3W $21.87 -89.62% -11.52% +78.10
Leana < 20 9/13/2006 Underperform 3W $10.44 -78.26% -13.51% +64.74
ErnestLim168 94.13 2/1/2007 Underperform 5Y $14.68 -84.54% -21.16% +63.38
sund3vil < 20 1/26/2007 Underperform 1Y $13.67 -83.39% -20.04% +63.35
xavierg 39.05 2/5/2007 Underperform 3W $13.35 -83.00% -21.42% +61.58
ChrisJr03 < 20 2/26/2007 3/22/2009 Underperform 1Y $13.04 -82.59% -22.03% +60.57
anticitradeshort 25.36 4/20/2009 Underperform NS $3.39 -33.04% +26.54% +59.58
zudnic 32.03 11/17/2006 Underperform 5Y $9.68 -76.55% -18.79% +57.76 1 Comment
twafer 89.46 12/12/2006 10/16/2007 Underperform 1Y $9.18 -75.27% -19.60% +55.67
Ahote 54.25 6/20/2007 Underperform 3M $12.62 -82.01% -26.39% +55.62

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackLeerinkSwan 84.26 5/28/2008 Underperform NS $4.70 +1.28% +0.22% -1.06 5/28/2008 @ $4.76
TrackBearStearns 86.38 12/14/2007 Underperform NS $4.81 -52.81% -24.13% +28.68
TrackJefferies 75.83 12/13/2007 Underperform NS $5.20 -56.35% -24.36% +31.98
TrackSoros 65.62 9/30/2007 Outperform NS $10.00 -77.30% -26.44% -50.86 1 Comment
TrackLehmanBros 76.60 1/17/2007 Outperform NS $12.32 -59.25% -5.38% -53.88 2/14/2008 @ $5.02
TrackJimCramer < 20 4/4/2006 Outperform 3W $63.15 -96.41% -12.13% -84.28

Featured Broker Partners